港股異動丨手機產業鏈股普升 舜宇、丘鈦升3.2% 瑞聲升近3%
港股手機產業鏈股普遍上升,其中,舜宇光學、丘鈦科技升3.2%,瑞聲科技、高偉電子升近3%,富智康集團、比亞迪電子升超2%。消息上,2024年,智能手機市場強勢回暖,市場分析機構Canalys在2月5日發佈的報吿顯示,2024年全球智能手機市場增長7%,出貨量達到12.2億部,成功扭轉了連續兩年下滑的局面。Canalys分析師指出,“國補”政策為中國智能市場2025年的發展打下基礎,終端廠商已陸續開展渠道和供應的前期準備工作。Canalys預測,2025年,補貼政策將推動中國智能手機市場出貨量增長,出貨量預計超過2.9億部。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.